This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors
Blood Cancer Journal Open Access 20 December 2022
-
Emerging roles of spliceosome in cancer and immunity
Protein & Cell Open Access 01 July 2021
-
Functional significance of U2AF1 S34F mutations in lung adenocarcinomas
Nature Communications Open Access 13 December 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cazzola M, Invernizzi R . Ring sideroblasts and sideroblastic anemias. Haematologica 2011; 96: 789–792.
Hasserjian RP, Gatterman N, Bennett JM, Brunning RD, Thiele J . Refractory anemia with ring sideroblasts. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn. IARC: Lyon, France, 2008, pp 96–97.
Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010; 28: 3858–3865.
Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006; 108: 2173–2181.
Wang SA, Hasserjian RP, Loew JM, Sechman EV, Jones D, Hao S et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia 2006; 20: 1641–1644.
Boissinot M, Garand R, Hamidou M, Hermouet S . The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood 2006; 108: 1781–1782.
Renneville A, Quesnel B, Charpentier A, Terriou L, Crinquette A, Lai JL et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 2006; 20: 2067–2070.
Gattermann N, Billiet J, Kronenwett R, Zipperer E, Germing U, Nollet F et al. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600 × 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood 2007; 109: 1334–1335.
Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424–2433.
Will CL, Luhrmann R . Spliceosome structure and function. Cold Spring Harb Perspect Biol 2011; 3: a.003707.
Ward AJ, Cooper TA . The pathobiology of splicing. J Pathol 2010; 220: 152–163.
Link DC, Schuettpelz LG, Shen D, Wang J, Walter MJ, Kulkarni S et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 2011; 305: 1568–1576.
Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A . JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 2011; 25: 218–225.
Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011; 25: 1153–1158.
Tehranchi R, Invernizzi R, Grandien A, Zhivotovsky B, Fadeel B, Forsblom AM et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 2005; 106: 247–253.
Guernsey DL, Jiang H, Campagna DR, Evans SC, Ferguson M, Kellogg MD et al. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet 2009; 41: 651–653.
Acknowledgements
The work was supported by Celgene Future Leaders of Hematology Award and Cleveland Clinic Institutional Seed Support (RVT); National Institutes of Health grants R01-HL082983 (JPM), U54-RR019391 (JPM and MAS) and K24-HL077522 (JPM); and a charitable donation from Robert Duggan Cancer Research Foundation. The Framingham Heart Study is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University (contract no. N01-HC-25195). This manuscript was not prepared in collaboration with investigators of the Framingham Heart Study and does not necessarily reflect the opinions or views of the Framingham Heart Study, Boston University or NHLBI.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Visconte, V., Makishima, H., Jankowska, A. et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 26, 542–545 (2012). https://doi.org/10.1038/leu.2011.232
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.232
This article is cited by
-
In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors
Blood Cancer Journal (2022)
-
Emerging roles of spliceosome in cancer and immunity
Protein & Cell (2022)
-
Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group
Modern Pathology (2022)
-
Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations
Leukemia (2021)
-
Complex landscape of alternative splicing in myeloid neoplasms
Leukemia (2021)